Since April 2015, David Eansor has been Senior Vice President of the Biotech Division of Bio-Techne Corporation (NASDAQ: TECH), a leading developer and manufacturer of high quality purified proteins — notably cytokines and growth factors, antibodies, immunoassays, as well as biologically active small molecule compounds. He has P&L responsibility for the largest division of Bio-Techne which includes the R&D Systems, Novus and Tocris brands of assays, proteins, antibodies, small molecules and cell culture products. From 2013 to 2015, Mr. Eansor was Senior Vice President of Novus Biologicals, which was acquired by Bio-Techne in July 2014. Prior to joining Novus Biologicals, Mr. Eansor was the President of the Life Science Research business of Thermo Fisher Scientific from 1996 to 2010, and then was promoted to serve as the President of the Bioscience Division of Thermo Fisher from 2010 to 2013. Mr. Eansor has a BSc in Chemistry from University of Western Ontario, a Bachelor of Commerce in General Business and Economics, and an MBA from the University of Windsor, Ontario, Canada.
Throughout his career, Mr. Elms has held numerous leadership roles in the healthcare sector. Mr. Elms currently serves as Managing Partner at Aisling Capital, a leading life sciences investment firm. Prior to joining Aisling, he was a Principal in the Life Sciences Investment Banking Group of Chase H&Q (formerly Hambrecht & Quist), where he was involved in over 60 financing and M&A transactions, helping clients raise in excess of $3.3 billion in capital. Prior to H&Q, Mr. Elms traded mortgage-backed securities at Donaldson, Lufkin & Jenrette. His previous healthcare sector experience includes over two years as a pharmaceutical sales representative for Marion Laboratories and two years as a consultant for The Wilkerson Group. Mr. Elms currently serves as a director of ADMA Biologics, Ajax Health II and Zosano Pharma and was previously Chairman of the Board of LOXO Oncology. He also serves on the INVO Board at Northwestern University. He received his M.B.A. from the Kellogg Graduate School of Management at Northwestern University and his B.A. in Human Biology from Stanford University.
Peter L. Hoang brings over twenty years of investment banking, venture capital, immuno-oncology and public company executive management experience to Marker Therapeutics, Inc., serving most recently as President & CEO of TapImmune Inc. (Nasdaq: TPIV), one of the predecessor companies that merged to form Marker Therapeutics. He has also served as Senior Vice President of Business Development & Strategy at Bellicum Pharmaceuticals (Nasdaq: BLCM). Previously, as the Managing Director of Innovations at The University of Texas MD Anderson Cancer Center, he headed the new venture formation and development effort for the institution. There, he led the commercialization of MD Anderson’s Sleeping Beauty transposon-based CAR-T program, resulting in the largest public company-to-academic research institution upfront deal in history. Before joining MD Anderson, Mr. Hoang was a Managing Director and head of healthcare mergers & acquisitions advisory for CIT Group (NYSE: CIT). He also served as a senior investment banker in the M&A departments at Oppenheimer, J.P. Morgan, Merrill Lynch, and Deutsche Bank. He earned an M.B.A. with high honors distinction from the Anderson School of Management at UCLA and a B.A. from Yale University.
David Laskow-Pooley, a Pharmacist by profession, founded Pharmafor ltd, a company providing specialist assistance to small and emerging enterprises in the medical technology sector. Having successfully been responsible for and involved in several spin-outs and start-ups he now focuses this knowledge and experience into assisting a portfolio of start-ups and growth companies. David is also CEO to one such company, London Pharma, a company re-purposing known molecules to new or improved uses. It has completed a phase III treatment for severe malaria in children and has embarked upon a Phase II treatment for cancers. Prior to this he has held a number of director, executive officer and general management posts in both small and major multinational companies including GSK plc, Abbott inc (now Abbvie inc), Amersham plc (now GEMS), Life Technologies inc, OSI inc (now Astellas), Bilcare and Surface Therapeutics. These have spanned the full range of activities ranging from discovery, through manufacturing to sale of pharmaceutical products, diagnostics and devices. He is a non-executive director of OBN Ltd, a highly successful trade association for SME enterprises in the Life Sciences sector.
For the past 12 years, Juan F. Vera has worked extensively on developing novel T cell therapies and optimizing manufacturing processes for clinical applications at the Center for Cell and Gene Therapy (CAGT) at Baylor College of Medicine. In collaboration with Wilson Wolf Manufacturing, he has been instrumental in the design and testing of the G-Rex® cell culture platform and pioneered its use for the large-scale production of T cells. Dr. Vera has extensive expertise in developing and streamlining therapeutic candidates from the research bench to the cGMP facility while ensuring robust production and scalability. Dr. Vera has previously collaborated with Celgene and Bluebird Bio in developing novel CAR T cell therapies. He has also been the recipient of different prestigious awards including the Idea Development Award from the Department of Defense and Mentored Research Scholar Award from the American Cancer Society. Dr. Vera attained his M.D. from the University El Bosque in Bogota, Colombia.
Frederick (Rick) Wasserman is an accomplished Board Director with 35 years of business experience. He has served during his career as President, COO and CFO of entrepreneurial, middle-market companies. Rick has a strong financial background which he has successfully focused on all aspects of company operations including cash flow, profitability and equity valuation. He has served as a member of Audit and Corporate Governance Committees for public companies in the U.S. and Europe. In his role as President of FGW Partners LLC, Pennington, New Jersey, he has assisted small and micro-cap companies at transitional points in their evolutions. This has included focus on corporate governance, investment analysis and liquidity management, as well as general financial and operational issues. Rick was a Certified Public Accountant who held staff positions through Audit Manager for three accounting firms. He has a B.S. in Economics from the Wharton School, University of Pennsylvania, PA.
John R. Wilson is Managing Director of ViraCyte, LLC, and the CEO of Wilson Wolf Manufacturing. Mr. Wilson has over 30 years of experience in the design, development and manufacture of products for the field of biotechnology, including cell culture devices and bioreactors. Mr. Wilson has obtained over 50 related patents with numerous patents currently pending. He is the co-inventor of the G-Rex® platform, which has revolutionized T cell manufacturing practices with its simple, reliable and scalable cell production. Mr. Wilson is also the co-inventor of the CELLineTM product line. Prior to co-founding Wilson Wolf Manufacturing and ViraCyte, Mr. Wilson was a principal mechanical engineer at Cellex Biosciences (now The Cell Culture Company) where he contributed to the world’s first commercially available fully-automated hollow fiber bioreactor cell culture system. Mr. Wilson has a BA in Business Administration and a BA in Economics from Hamline University in Minnesota and a B.S. in Mechanical Engineering from the University of Minnesota.